# 9. Conclusion and Future Work

## 9.1 Conclusion
We presented an Evidence-Conditioned Compositional Pipeline Synthesis framework that bridges published biomedical literature to executable, safe, and reproducible clinical prediction pipelines. The framework enforces strict provenance tracking, bars arbitrary library defaults, prevents target data leakage, and provides immutable execution contracts.

Empirical evaluation on the retrospective HANCOCK clinical tabular cohort demonstrated strong internal discriminative performance (mean ROC-AUC `0.9751 ± 0.0114`) and probability calibration (Brier score `0.0175`), achieving a modest improvement over Default XGBoost (`0.9704 ± 0.0059`). Controlled ablations demonstrated the vital distinction between evidence-backed validity and empirical dataset optimality. The primary contribution of this work is the principled, provenance-aware synthesis methodology and governance framework for reproducible clinical machine learning.

## 9.2 Prioritized Future Directions
Future research should focus on:
1. **External Multi-Center Validation**: Evaluating synthesized pipelines across geographically diverse hospital systems.
2. **Prospective Clinical Studies**: Assessing real-time risk stratification and clinical workflow utility.
3. **Statistical Resampling Expansion**: Scaling to $n \ge 30$ seeds or repeated nested cross-validation for formal inferential testing.
4. **Automated Risk-of-Bias Scoring**: Integrating automated study quality appraisal (e.g., PROBAST criteria) into literature extraction.
5. **Interactive Clinician Review**: Developing human-in-the-loop interfaces for clinical expert oversight.
6. **Multi-Modal Evidence Synthesis**: Extending synthesis to imaging, pathology text, and genomics.
